The FDA has granted approval for Johnson & Johnson’s Rybrevant (amivantamab-vmjw) in combination with chemotherapy for treating advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval marks the third new indication for Rybrevant this year, highlighting its potential as a treatment option for patients with advanced NSCLC.